Lloyd Klickstein

Lloyd Klickstein is a founder of Versainis and currently serves as Chief Scientific Officer and a member of the Board of Directors. Lloyd has nearly 20 years of experience as an industry executive. Prior to co-founding Versanis, he was Chief Innovation Officer at Adicet Bio and Chief Scientific Officer at resTORbio. Before that he served for 13 years as Head of Translational Medicine for Musculoskeletal Diseases and the New Indication Discovery Unit at the Novartis Institutes for Biomedical Research (NIBR). In that role, drug development responsibilities extended from target identification through global phase 3 development. Additional responsibilities included research and early clinical development board memberships, clinical safety board membership and business development. Prior to Novartis, Dr. Klickstein was an academic physician-scientist at Brigham & Women’s Hospital (BWH) in Boston, where he directed an NIH-funded basic science laboratory and maintained an active clinical practice in the Arthritis Center.

Dr. Klickstein received his B.S. degree from Tufts University, his M.D. and Ph.D. degrees from Harvard University, completed post-graduate clinical training at BWH and was Board-certified and re-certified in Internal Medicine and Rheumatology & Immunology and completed a post-doctoral research fellowship at the Center for Blood Research in Boston.